Risk Stratification in Cardiac Sarcoidosis With Cardiac Positron Emission Tomography: A Systematic Review and...

Area of Science:

• Cardiology
• Nuclear Medicine
• Oncology

Background:

• Cardiac sarcoidosis diagnosis relies on Positron Emission Tomography (PET) imaging, but its prognostic capabilities for major adverse cardiac events (MACE) require further elucidation.
• Risk stratification for MACE in cardiac sarcoidosis patients using PET imaging is an area needing more research.

Approach:

• A systematic review and meta-analysis was conducted to evaluate the prognostic value of PET imaging in cardiac sarcoidosis.
• Extensive literature searches were performed across multiple databases including EMBASE, MEDLINE, PubMed, and Cochrane.
• The primary outcome assessed was the occurrence of MACE in patients with cardiac sarcoidosis.

Key Points:

• Abnormal fluorodeoxyglucose (FDG) uptake and perfusion defects on PET scans were associated with increased MACE risk (OR 2.86).
• Focal abnormal right ventricular uptake (OR 6.27) and lack of response to immunosuppression on serial PET (OR 8.43) were particularly strong predictors of MACE.
• Analysis indicated a low to moderate risk of bias across the included studies, though sample sizes varied.

Conclusions:

• Cardiac PET imaging parameters are valuable for risk stratification in patients with cardiac sarcoidosis.
• Specific findings such as focal right ventricular uptake and non-response to immunosuppressive therapy on serial PET are highly predictive of MACE.